Atlas Trials

T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Clinical trial NCT07474168 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT07474168
Sponsor
Zhejiang University
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Tumor
Start date
2025-12-15
Primary completion
2027-02-01
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.